Research programme: CCL5 inhibitors - Afecta Pharmaceutical
Alternative Names: add RANTES inhibitors - Afecta Pharmaceutical; CCL5/RANTES pathway inhibitors - Afecta PharmaceuticalLatest Information Update: 29 Sep 2023
At a glance
- Originator Afecta Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Chemokine CCL 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation